Loading...
Market
Story
Novavax, Sanofi Ink $1.2 Billion Deal for COVID-19 and Flu Vaccines; Stock Soars
May 10, 2024, 11:02 AM
Novavax has entered into a multibillion-dollar licensing agreement with Sanofi to commercialize a COVID-19 vaccine and develop combination vaccines for COVID-19 and influenza. The deal, valued up to $1.2 billion, includes an upfront payment of $500 million from Sanofi to Novavax. Sanofi will also acquire a 4.9% equity stake in Novavax, significantly boosting the U.S. biotech's market value. This partnership aims to enhance vaccine sales post-pandemic and provides Novavax with a substantial financial boost, reflected in a 40% surge in its stock price.
View original story
Similar markets
Top performer • 33%
Average performer • 34%
Below average performer • 33%
Increase over 200% • 25%
Increase 100-200% • 25%
Increase up to 100% • 25%
Decrease or no change • 25%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
10-20% increase • 25%
21-50% increase • 25%
51-100% increase • 25%
more than 100% increase • 25%
Over 50 countries • 25%
30-50 countries • 25%
10-29 countries • 25%
Under 10 countries • 25%